Revance Therapeutics (RVNC) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Revance Theraputics (RVNC) Pipeline is Underappreciated - Guggenheim
March 3, 2016 9:05 AM ESTGuggenheim analyst, Louise Chen, believes Revance Therapeutics' (NASDAQ: RVNC) pipeline prospects are underappreciated. She expects five launches over five years beginning in '19 that should drive upward earnings revisions and multiple expansion to levels not reflected in consensus expectations. No change to Buy rating or $55 PT.
The launches include:
1) RT001, topical for Crows Feet Lines in '19
2) RT002, injectable for glabellar... More
